The SM Journey: Sharing
Explore insights and strategies for managing the disease long-term.
-
-
Study will assess HMA and KIT inhibitors to treat SM subtype
-
Managing health insurance and deductibles with SM
-
FDA approves new liquid form of imatinib to treat some forms of SM
-
Bezuclastinib shows promise in treating nonadvanced systemic mastocytosis
-
Study confirms that KIT-inhibitor therapy improves prognosis in advanced SM
-
Losing weight for my health with indolent SM
